BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
80 hedge funds and large institutions have $115M invested in BRAINSTORM CELL THERAPUTC in 2020 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 27 increasing their positions, 15 reducing their positions, and 14 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 15
64% more capital invested
Capital invested by funds: $70M → $115M (+$45.1M)
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
5% more funds holding
Funds holding: 76 → 80 (+4)
0.03% more ownership
Funds ownership: 1.41% → 1.44% (+0.03%)
53% less call options, than puts
Call options by funds: $17.6M | Put options by funds: $37.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$5.03M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$3.25M |
| 3 |
SG Americas Securities
New York
|
+$1.19M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$1.17M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$882K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.11M |
| 2 |
Renaissance Technologies
New York
|
-$1.58M |
| 3 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$1.11M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$474K |
| 5 |
D.E. Shaw & Co
New York
|
-$425K |
BCLI Hedge Fund Activity: Q3 2020 in Review
80 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q3 2020, worth a combined $115M — up 64% from $70M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new BCLI positions and 14 closed out — a net gain of 4 holders — while 27 added to existing stakes and 15 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $5.03M. The largest seller was Vanguard Group, cutting an estimated $2.11M.
- 80 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q3 2020, up from 76 in Q2 2020.
- Funds reported $115M of BRAINSTORM CELL THERAPUTC stock for Q3 2020, up 64% quarter-over-quarter.
- 18 funds opened new BRAINSTORM CELL THERAPUTC positions in Q3 2020 and 14 closed out, a net change of +4 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q3 2020 was Invesco, an estimated $5.03M added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q3 2020 was Vanguard Group, an estimated $2.11M sold.
Based on aggregated 13F filings for Q3 2020.